Abstract:Intratumoral hypoxia significantly constrains the susceptibility of solid tumors to oxygen-dependent photodynamic therapy (PDT), and effort to reverse such hypoxia has achieved limited success to date. Herein, we developed a novel engineered bacterial system capable of targeting hypoxic tumor tissues and efficiently mediating the photodynamic treatment of these tumors. For this system, we genetically engineered Escherichia coli to express catalase, after which we explored an electrostatic adsorption approach to link black phosphorus quantum dots (BPQDs) to the surface of these bacteria, thereby generating an engineered E. coli/BPQDs (EB) system. Following intravenous injection, EB was able to target hypoxic tumor tissues. Subsequent 660 nm laser irradiation drove EB to generate reactive oxygen species (ROS) and destroy the membranes of these bacteria, leading to the release of catalase that subsequently degrades hydrogen peroxide to yield oxygen. Increased oxygen levels alleviate intratumoral hypoxia, thereby enhancing BPQD-mediated photodynamic therapy. This system was able to efficiently kill tumor cells in vivo, exhibiting good therapeutic efficacy. In summary, this study is the first to report the utilization of engineered bacteria to facilitate PDT, and our results highlight new avenues for BPQD-mediated cancer treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c20254?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c20254</a>.Materials, methods, oxygen generation in 3% H2O2 solution after different bacteria lysis treatments as measured by a dissolved oxygen meter (Figure S1); AFM image of BPQDs (Figure S2); absorbance spectra of EB before and after rotation (Figure S3); height profiles of the BPQDs (Figure S4); CLSM photo of pure E. coli modified with DSPE-PEG-Cy5 (Figure S5); DCFH-DA fluorescence intensity (Figure S6); viability of E. coli survival rate (Figure S7); blood biochemistry data of kidney function markers: CRE and BUN (Figures S8 and S9); blood biochemistry data of liver function markers: ALT, ALP, and AST (Figure S10); histopathologic examination of tissues (Figure S11); and DCFH-DA fluorescence intensity (Figure S12) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c20254/suppl_file/am0c20254_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Genetically Engineered Bacteria as A Living Bioreactor for Monitoring and Elevating Hypoxia‐Activated Prodrug Tumor Therapy

A dual-response drug delivery system with X-ray and ROS to boost the anti-tumor efficiency of TPZ <i>via</i> enhancement of tumor hypoxia levels

Modulating Tumour Vascular Normalisation Using Triptolide-Loaded NGR-functionalized Liposomes for Enhanced Cancer Radiotherapy

Nanoparticles Conjugated with Bacteria Targeting Tumors for Precision Imaging and Therapy.

Improving the Therapeutic Efficiency of Hypoxic-Activated Prodrugs by Enhancing Hypoxia in Solid Tumors

Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers

Biomimetic cell membrane-coated glucose/oxygen-exhausting nanoreactor for remodeling tumor microenvironment in targeted hypoxic tumor therapy

Anti-LDLR modified TPZ@Ce6-PEG complexes for tumor hypoxia-targeting chemo-/radio-/photodynamic/photothermal therapy

Phosphorescence Monitoring of Hypoxic Microenvironment in Solid-Tumors to Evaluate Chemotherapeutic Effects Using the Hypoxia-Sensitive Iridium (III) Coordination Compound.

Novel Engineered Bacterium/Black Phosphorus Quantum Dot Hybrid System for Hypoxic Tumor Targeting and Efficient Photodynamic Therapy

Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy

TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity

Tumor acidity/redox hierarchical-activable nanoparticles for precise combination of X-ray-induced photodynamic therapy and hypoxia-activated chemotherapy.

Radiation-/hypoxia-induced Solid Tumor Metastasis and Regrowth Inhibited by Hypoxia-Specific Upconversion Nanoradiosensitizer

A novel hypoxia‐activated polymeric Tirapazamine derivative for enhanced antitumor therapy

Engineered biomimetic nanoreactor for synergistic photodynamic-chemotherapy against hypoxic tumor

Hypoxic Tumor Radiosensitization Using Engineered Probiotics

Novel Semiconducting Nano-Agents Incorporating Tirapazamine for Imaging Guided Synergistic Cancer Hypoxia Activated Photo-Chemotherapy.

Highly Active Nano-Reactor for Responding Tumor Microenvironment and Antitumor Therapy

Correction to Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy.

Hypoxia-specific therapeutic agents delivery nanotheranostics: A sequential strategy for ultrasound mediated on-demand tritherapies and imaging of cancer